Bill Alpert
Senior Writer at Barron's
Bill Alpert is a Senior Writer at Barron’s, where since 1984 he has published nerdy feature stories, columns and investigative projects of use to investors.
Articles
-
4 days ago |
barrons.com | Bill Alpert
American healthcare facilities can only fill half their nursing jobs. As the population ages and current nurses themselves retire, the shortage could get worse.
-
6 days ago |
barrons.com | Bill Alpert
Grail’s cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation on Monday. The company’s Galleri product screens a blood sample for the genetic debris of cancer, which can appear long before any symptoms. Grail hopes its multicancer blood test will eventually become part of routine checkups.
-
6 days ago |
barrons.com | Bill Alpert
Grail cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation on Monday. The company’s Galleri product screens a blood sample for the genetic debris of cancer, which can appear long before any symptoms. Grail hopes its multicancer blood test will eventually become part of routine checkups.
-
1 week ago |
barrons.com | Bill Alpert
Investors looking for a place to ride out a possible recession might want to consider the stocks of insurance brokers.
-
1 week ago |
barrons.com | Bill Alpert
Enthusiasm waned on Wall Street for weight-loss drug pioneer Novo Nordisk, after a pill tested by rival Eli Lilly produced as much weight loss as Novo’s injectable Ozempic. Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman at BMO Capital Markets.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 941
- DMs Open
- Yes
Is the #SEC blindfolding its stock market cops ? The SEC Is Considering Blunting Its Trade-Tracking System https://t.co/8vMDIvJEAT via @BarronsOnline
This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. - Barron's https://t.co/DltWCAyEgX
#statefarm made itself too big to fail California Allows State Farm’s Emergency 22% Hike in Homeowner’s Insurance Rates https://t.co/zuyqmu1HOc via @BarronsOnline